Catalyst Biosciences Inc. (NASDAQ: CBIO) is -9.05% lower on its value in year-to-date trading and has touched a low of $0.06 and a high of $0.40 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CBIO stock was last observed hovering at around $0.27 in the last trading session, with the day’s gains setting it 0.03% off its average median price target of $3.00 for the next 12 months. It is also 90.0% off the consensus price target high of $3.00 offered by 2 analysts, but current levels are 90.0% higher than the price target low of $3.00 for the same period.
Currently trading at $0.30, the stock is -8.75% and -9.52% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.61 million and changing 10.00% at the moment leaves the stock 10.23% off its SMA200. CBIO registered 185.16% gain for a year compared to 6-month gain of 3.69%.
The stock witnessed a -4.05% loss in the last 1 month and extending the period to 3 months gives it a -16.82%, and is 16.61% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.12% over the week and 10.20% over the month.
Catalyst Biosciences Inc. (CBIO) has around 45 employees, a market worth around $10.46M and $3.20M in sales. Current P/E ratio is 0.79. Distance from 52-week low is 421.28% and -26.19% from its 52-week high. The company has generated returns on investments over the last 12 months (-213.90%).
Catalyst Biosciences Inc. (CBIO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Catalyst Biosciences Inc. (CBIO) is a “Hold”. 2 analysts offering their recommendations for the stock have an average rating of 2.70, where 2 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Catalyst Biosciences Inc. is expected to release its quarterly report on 05/04/2023.The EPS is expected to grow by 2.10% this year.
Catalyst Biosciences Inc. (CBIO) Top Institutional Holders
The shares outstanding are 31.48M, and float is at 27.91M with Short Float at 3.43%.
Catalyst Biosciences Inc. (CBIO) Insider Activity
A total of 3 insider transactions have happened at Catalyst Biosciences Inc. (CBIO) in the last six months, with sales accounting for 0 and purchases happening 3 times.
Catalyst Biosciences Inc. (CBIO): Who are the competitors?
The company’s main competitors (and peers) include AstraZeneca PLC (AZN) that is trading 12.15% up over the past 12 months and Johnson & Johnson (JNJ) that is 2.09% higher over the same period. AbbVie Inc. (ABBV) is 11.90% up on the 1-year trading charts.